达帕格利弗洛辛和身体和社会活动的限制在心力衰竭中与减少的射出分数
Jawad H Butt1, Kieran F Docherty2, Mikhail N Kosiborod3
1British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
JACC. Heart failure
|June 15, 2023
概括
达帕格利弗洛辛显著改善了心力衰竭患者的身体和社会活动限制,心力衰竭患者的心力衰竭率减少 (HFrEF). 这种治疗改善了日常功能和生活质量,根据堪萨斯城心肌病问卷 (KCCQ) 的测量.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 心力衰竭 (HF) 显著影响身体功能和生活质量.
- 高压对健康状况的影响比许多其他慢性疾病更为深刻.
研究的目的:
- 评估达帕格利弗洛辛对心力衰竭患者身体和社会限制的影响.
- 在DAPA-HF试验中使用堪萨斯城心肌病问卷 (KCCQ) 分析患者报告的结果.
主要方法:
- 使用混合效应模型和响应者分析来评估KCCQ分数的变化.
- 该研究检查了个人身体和社会活动限制问题以及总体得分.
- 分析了4269名患者在基线和3955名患者在8个月后的数据.
主要成果:
- 与安慰剂相比,达帕格利弗洛辛显著改善了KCCQ物理和社会活动限制得分的平均值 (平均差异分别为1.94和1.84).
- 在所有身体和社会限制的个体组件中都观察到改善,特别是在爱好和家务方面.
- 在接受达帕格利弗洛辛治疗的患者中,更高比例的患者在活动限制得分中经历了5分的改善.
结论:
- 达帕格利弗洛辛在HFrEF患者的身体和社会活动限制方面显著改善.
- 这些发现表明,达帕格利弗洛辛对HF患者的日常功能和生活质量产生了积极的影响.
- 该DAPA-HF试验提供了证据,证明达帕格利弗洛辛的益处超出了传统的HF管理.
相关概念视频
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
01:30Heart Failure VII: Nursing Interventions
118
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
118